MedTrace Logo

Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients

NCT02588859 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2017-12-19

No results posted yet for this study

Summary

This is a multicentre, non-interventional, prospective, observational study which would be conducted in India to understand the usage and effect of saxagliptin as first add-on therapy after metformin. The study will enroll Type 2 Diabetes Mellitus (T2DM) patients who were inadequately controlled with metformin alone and have been recently prescribed saxagliptin as an add-on to metformin.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Dr Sanjay Kalra, MD, DM (Endocrinology) · Bharti Research Institute of Diabetes & Endocrinology, Karnal

  • Dr Bhavesh P Kotak, FRCS, MS, D Orth · AstraZeneca Pharma India Ltd

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-30
Primary Completion
2016-12-26
Completion
2016-12-26

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588859 on ClinicalTrials.gov